Pharmacogenomics in personalized treatment plans for Alzheimer's disease report
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Current pharmacotherapy for Alzheimer's disease relies heavily on a one-size-fits-all dosing paradigm that ignores the profound interindividual variability in drug metabolism, receptor sensitivity, and treatment response that genetic polymorphisms create [1]. This research evaluated a pharmacogenomics-guided treatment approach against standard care and placebo in 178 patients with mild-to-moderate Alzheimer's disease enrolled at two Danish university hospitals between March 2020 and December 2021. Participants in the pharmacogenomics arm (n=62) underwent genotyping for APOE, CYP2D6, CYP3A4, and ABCB1 variants, with drug selection and dosing individualized according to their metabolizer profiles. Standard therapy participants (n=59) received conventional cholinesterase inhibitor treatment, while the placebo group (n=57) received matched placebo capsules. The primary endpoint was cognitive decline measured by the Alzheimer's disease Assessment Scale-Cognitive Subscale (ADAS-Cog) at 18 months. Secondary endpoints included Mini-Mental State Examination (MMSE) trajectories, cerebrospinal fluid biomarker changes, adverse event rates, and caregiver burden scores. The pharmacogenomics-guided group demonstrated significantly less cognitive decline on ADAS-Cog (-3.8 points versus -1.4 for standard and +2.7 for placebo, p
Fields of Study & Subjects
Pharmacogenetics and Drug Metabolism
Alzheimer's disease research and treatments
Dementia and Cognitive Impairment Research
Publication details
- Journal / source
- International Journal of Pharmaceutical and Clinical Research
- Volume
- 8
- Issue
- 3
- Pages
- 20–25
- Publication date
- 1 March 2026
- Language
- EN